FDA Approves First Chinese Cancer Drug for U.S. Patient Use
- Beijing-based BeiGene’s Brukinsa treats blood cancer
- New drug will compete with therapies from AbbVie, AstraZeneca
This article is for subscribers only.
The U.S. Food and Drug Administration has granted approval to a blood cancer drug from Beijing-based BeiGene Ltd., paving the way for American patients to access a Chinese cancer therapy for the first time.
The accelerated approval -- ahead of even China’s own national drug regulator -- marks a breakthrough for the growing legion of Chinese biotech companies determined to take on the world’s biggest pharmaceutical companies in medical innovation and scientific research.